RPR early access program for Rilutek will treat 10,000 patients worldwide prior to approval.
RPR PROVIDING RILUTEK TO 10,000 ALS PATIENTS WORLDWIDE in the company's early access program prior to approval of the drug. The program for patients with amyotrophic lateral sclerosis (Lou Gehrig's disease), announced by Rhone-Poulenc Rorer on June 22, will begin by registering patients through July 20. On July 24, over 1,000 patients will be selected to receive initial treatment with Rilutek (riluzole) gratis through a computerized random selection process.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth